Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study
Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study
复制标题
DOI：
10.1136/ard.2011.154799
复制
发表时间：
2012-05-01
影响因子：
27.4
通讯作者：
Hsu, Benjamin
中科院分区：
文献类型：
--
作者：
Braun, Juergen;Deodhar, Atul;Hsu, Benjamin
目的评价戈利玛单抗治疗活动期强直性脊柱炎的疗效和安全性。方法将356例活动期强直性脊柱炎患者随机分为3组，每4周一次皮下注射安慰剂(1：1.8：1.8)、戈利玛单抗50 mg(组2)和戈利玛单抗100 mg(组3)。在第16周，组1和组2的患者
Objective To assess the efficacy and safety of golimumab over 104 weeks in patients with active ankylosing spondylitis.Methods At baseline, patients with active ankylosing spondylitis (n=356) were randomly assigned (1:1.8:1.8) to subcutaneous injections of placebo (group 1), golimumab 50 mg (group 2) or golimumab 100 mg (group 3) every 4 weeks. At week 16, patients in groups 1 and 2 with